Sichuan Kelun Pharmaceutical Co Ltd
SZSE:002422

Watchlist Manager
Sichuan Kelun Pharmaceutical Co Ltd Logo
Sichuan Kelun Pharmaceutical Co Ltd
SZSE:002422
Watchlist
Price: 30.49 CNY -3.57% Market Closed
Market Cap: 46.7B CNY
Have any thoughts about
Sichuan Kelun Pharmaceutical Co Ltd?
Write Note
Sichuan Kelun Pharmaceutical Co Ltd
/
Cash Flow Statement
/
Cash from Operating Activities

Sichuan Kelun Pharmaceutical Co Ltd
Cash from Operating Activities

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Sichuan Kelun Pharmaceutical Co Ltd
Cash from Operating Activities Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Cash from Operating Activities CAGR 3Y CAGR 5Y CAGR 10Y
Sichuan Kelun Pharmaceutical Co Ltd
SZSE:002422
Cash from Operating Activities
¥4.4B
CAGR 3-Years
13%
CAGR 5-Years
7%
CAGR 10-Years
13%
H
Hansoh Pharmaceutical Group Company Ltd
HKEX:3692
Cash from Operating Activities
¥3.1B
CAGR 3-Years
9%
CAGR 5-Years
9%
CAGR 10-Years
N/A
Zhangzhou Pientzehuang Pharmaceutical Co Ltd
SSE:600436
Cash from Operating Activities
¥1.2B
CAGR 3-Years
0%
CAGR 5-Years
-5%
CAGR 10-Years
17%
Jiangsu Hengrui Pharmaceuticals Co Ltd
SSE:600276
Cash from Operating Activities
¥7.9B
CAGR 3-Years
39%
CAGR 5-Years
19%
CAGR 10-Years
18%
Yunnan Baiyao Group Co Ltd
SZSE:000538
Cash from Operating Activities
¥4.5B
CAGR 3-Years
-2%
CAGR 5-Years
N/A
CAGR 10-Years
15%
S
Sichuan Biokin Pharmaceutical Co Ltd
SSE:688506
Cash from Operating Activities
-¥615.4m
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
No Stocks Found

Sichuan Kelun Pharmaceutical Co Ltd
Glance View

Market Cap
48.8B CNY
Industry
Pharmaceuticals

Sichuan Kelun Pharmaceutical Co., Ltd., established in 1997 and headquartered in Chengdu, China, has rapidly emerged as a formidable player in the pharmaceutical industry. The company specializes in the research, development, and production of a diverse range of pharmaceuticals, including innovative drugs, generic medications, and active pharmaceutical ingredients (APIs). Kelun has built a strong reputation for its commitment to quality and safety, evidenced by its compliance with international regulatory standards and certifications such as FDA and EMA approvals. With a robust portfolio that spans key therapeutic areas like oncology, cardiovascular diseases, and infectious diseases, Kelun not only caters to the growing domestic demand but is also expanding its footprint in the global market, making it an appealing prospect for investors seeking growth in the health sector. As the pharmaceutical landscape in China evolves, fueled by increasing healthcare expenditures and an aging population, Kelun is strategically positioned to capitalize on these trends. The company's significant investments in research and development underscore its ambition to innovate and introduce new therapies that meet pressing healthcare needs. Furthermore, strategic collaborations with international partners enhance its technological capabilities and market reach. With strong financial metrics that reflect steady revenue growth and profitability, Kelun stands poised to leverage its operational expertise and strategic initiatives for sustained expansion. For investors, Sichuan Kelun Pharmaceutical represents an attractive opportunity to tap into the burgeoning pharmaceutical market led by a company marked by quality, innovation, and a clear vision for future growth.

Intrinsic Value
43.49 CNY
Undervaluation 30%
Intrinsic Value
Price
What is Intrinsic Value?

See Also

What is Sichuan Kelun Pharmaceutical Co Ltd's Cash from Operating Activities?
Cash from Operating Activities
4.4B CNY

Based on the financial report for Sep 30, 2024, Sichuan Kelun Pharmaceutical Co Ltd's Cash from Operating Activities amounts to 4.4B CNY.

What is Sichuan Kelun Pharmaceutical Co Ltd's Cash from Operating Activities growth rate?
Cash from Operating Activities CAGR 10Y
13%

Over the last year, the Cash from Operating Activities growth was -20%. The average annual Cash from Operating Activities growth rates for Sichuan Kelun Pharmaceutical Co Ltd have been 13% over the past three years , 7% over the past five years , and 13% over the past ten years .

Back to Top
ALPHA SPREAD
Follow us
Join more than 201,300+ value investors using Alpha Spread
Create a free account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks Wide Economic Moat Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2024 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.